#United States #Nashville #Cumberland Pharmaceuticals #Vibativ #Rx medications

Cumberland Pharmaceuticals Expands Vibativ Access

Cumberland Pharmaceuticals Inc. has recently made a significant move to extend the availability of its antibiotic Vibativ® (telavancin) through a new contract with Vizient®, which is recognized as the largest provider-driven healthcare performance improvement organization in the United States. This partnership allows for greater access to Vibativ's newly-configured 4-Vial Starter Pak, greatly benefiting both inpatient and outpatient healthcare environments.

Vizient serves a vast network of over 65% of the nation's acute care providers, which includes 97% of academic medical centers and a notable share of non-acute facilities. By entering into this agreement, Vizient members can efficiently start patient treatments with Vibativ, a powerful option in combating serious bacterial infections.

Enhanced Treatment Options

This latest offering from Cumberland Pharmaceuticals allows clinicians to initiate treatment flexibly and effectively, ensuring that patients have consistent access to a vital medication. A.J. Kazimi, the CEO of Cumberland Pharmaceuticals, expressed optimism about this expansion, emphasizing the benefits of delivering Vibativ in a manner that supports cost-effective healthcare across hospitals, infusion centers, and outpatient facilities nationwide.

Vibativ is a critically important antibiotic, having received FDA approval for use in treating serious infections including hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). Furthermore, it is indicated for complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria, notably including the notorious MRSA (Methicillin-resistant Staphylococcus aureus).

Versatile Availability

Apart from the Vibativ 4-Vial Starter Pak, the 12-vial carton configuration will also be accessible to Vizient provider clients via various distribution channels, enhancing the drug's availability across diverse healthcare settings. For more information on ordering, stakeholders can visit Vibativ's official site for detailed instructions.

Cumberland Pharmaceuticals continues to position itself as a leader in specialty pharmaceuticals, demonstrating commitment to improving healthcare outcomes through strategic partnerships and tailored product offerings. The Vibativ antibiotic has been meticulously developed, having undergone thorough research aimed at combating difficult bacterial infections caused by Gram-positive pathogens.

Vibativ: The Science Behind the Drug

This injectable medication is recognized not only for its once-daily administration but also for its significant potency and rapid bactericidal action. Studies reveal that Vibativ achieves effective concentration levels in targeted infection sites within just hours of administration, proving indispensable for those facing life-threatening infections due to S. aureus.

In clinical settings, Vibativ has thoroughly been analyzed against traditional treatments like vancomycin, showcasing favorable outcomes with higher cure rates in treating infections stemming from Gram-positive pathogens. This extensive study highlights its effectiveness, which is backed by clinical trials that include a broad patient cohort and extensively document the drug's in vitro and in vivo efficacy against challenging, multidrug-resistant infections.

Commitment to Patient Care

As the leading biopharmaceutical entity headquartered in Tennessee, Cumberland Pharmaceuticals remains dedicated to improving patient care through innovative solutions. The company’s portfolio also comprises other FDA-approved medications aimed at various medical conditions, underscoring its proactive approach in addressing urgent healthcare needs.

Overall, this contract with Vizient is poised to significantly enhance the accessibility of Vibativ, ultimately aiding healthcare professionals in their mission to treat and support patients battling serious infections. Cumberland Pharmaceuticals appears committed to continually advancing its efforts to deliver high-quality products designed to enhance patient outcomes in critical healthcare scenarios. For any medical inquiries or educational resources, Cumberland's Medical Affairs can be contacted directly via their official communication channels.

For detailed prescribing information, including usage guidelines and safety information, please visit Vibativ's website.